REPL — Replimune Group Inc

Founder-Led

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Replimune Group Inc

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors.… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$4.91
Market Cap$426M
Float58.5M
Shares Outstanding82.6M
vs. Analyst Target-28.7% to analyst PT
Dividend RateNone
Analyst Target Price$3.50 (8 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 N/A -$52.6M -$1.8M -$52.6M
2021 N/A -$80.9M -$4.1M -$76.5M
2022 N/A -$118M -$4.6M -$114M
2023 N/A -$174M -$2.4M -$172M
2024 N/A -$216M -$2.7M -$228M
2025 N/A -$247M -$3.5M -$254M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Mar 2025 $1.5M -$74.1M
Jun 2025 N/A -$86.7M
Sep 2025 N/A -$83.1M
Dec 2025 N/A -$70.9M

Ownership & Float

Insider Ownership2.7%
Institutional Ownership89.8%
Short Float36.2%
% of All Funds Holding2.06%
Number of Funds Holding169

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$4.87Near-term / short-term trend
Weekly40-Week SMA$6.86Medium-term trend
Weekly80-Week SMA$8.66Cyclical trend (business cycle)
Weekly200-Week SMA$12.59Secular trend (multi-year)
Monthly10-Month SMA$6.89Near-term monthly trend
Monthly20-Month SMA$8.91Medium-term monthly trend
Monthly40-Month SMA$11.15Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$7.70 resistance 1.85x 0 months ago
$2.60 support 1.31x 0 months ago

Historical Earnings Reactions (32 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -0.23% 0.57% 59.38% 5.83% -14.85%
1 Day 0.03% 0.30% 56.25% 16.44% -18.50%
1 Week -0.30% 1.42% 59.38% 9.25% -22.32%
2 Weeks -0.03% -1.02% 48.39% 16.21% -19.05%
1 Month 1.25% 2.38% 58.06% 29.55% -31.21%

Next earnings: May 28, 2026 (1 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan-1.4%62.5%8
Feb-5.1%37.5%8
Mar-8.8%25.0%8
Apr2.1%50.0%8
May-4.9%42.9%7
Jun22.3%85.7%7
Jul-8.8%28.6%7
Aug2.3%37.5%8
Sep-5.5%25.0%8
Oct26.8%62.5%8
Nov3.6%62.5%8
Dec-8.7%25.0%8

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday -0.20% 46.5% 370
Tuesday -0.07% 47.9% 405
Wednesday 0.61% 48.8% 402
Thursday 0.24% 50.8% 394
Friday 0.24% 50.6% 395

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 89.8%

Insider Transactions — Smart Summary

Total insider ownership: 2.7%

Founder-led management: Philip Astley-Sparke (Executive Chairman)

12-Month Insider Activity Summary

Total Filings12
Net Value-$710,320.9
Net Shares Change-131,446
% of Float-0.2%
C-Suite Filings10
Clusters Detected1

Key Insiders

NameTitleNet ValueFilingsActivity
Patel Sushil Chief Executive Officer -$300,905.92 2 N/A
Xynos Konstantinos Chief Medical Officer -$137,193.64 2 N/A
Sarchi Christopher Chief Commercial Officer -$95,885.08 2 N/A
Hill Emily Luisa Chief Financial Officer -$88,841.94 2 N/A
Schwendenman Andrew Chief Accounting Officer -$40,101.52 1 N/A
Dhingra Kapil -$27,411.85 1 1 sell

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2026-05-20 – 2026-05-20 6 6 -$474,146.88 5 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2025-12-11 Dhingra Kapil -$27,411.85 Transaction at $6.08, now -19.2%
2026-05-20 Xynos Konstantinos Chief Medical Officer -$71,236.84 Transaction at $5.08, now -3.3%
2026-05-20 Schwendenman Andrew Chief Accounting Officer -$40,101.52 Transaction at $5.08, now -3.3%
2026-05-20 Sarchi Christopher Chief Commercial Officer -$43,820.08 Transaction at $5.08, now -3.3%
2026-05-20 Patel Sushil Chief Executive Officer -$189,605.92 Transaction at $5.08, now -3.3%
2026-05-20 Hill Emily Luisa Chief Financial Officer -$39,684.96 Transaction at $5.08, now -3.3%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Replimune Group Inc (REPL) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for REPL on Trend Edge →